Comparative Pharmacology
Head-to-head clinical analysis: FORTEO versus FORTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTEO versus FORTICAL.
FORTEO vs FORTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human parathyroid hormone analog (1-34) that stimulates osteoblast activity, increasing bone formation and turnover.
Fortical (calcitonin salmon) is a synthetic polypeptide hormone that lowers blood calcium by inhibiting osteoclast-mediated bone resorption and increasing renal excretion of calcium and phosphate.
20 mcg subcutaneously once daily.
50 IU (0.25 mL) subcutaneously once daily, with calcium and vitamin D supplementation.
None Documented
None Documented
Terminal half-life: approximately 1 hour (subcutaneous administration). Clinically, the short half-life supports once-daily dosing; no accumulation observed with daily dosing.
Terminal elimination half-life: 43-51 minutes. Rapid clearance; requires twice-daily dosing for sustained calcium-lowering effect.
Renal (metabolites, primarily via glomerular filtration and tubular secretion; ~95% of absorbed dose eliminated in urine within 24 hours). Biliary/fecal: minimal (< 2%).
Renal: 50-70% of absorbed dose excreted unchanged in urine; fecal: 30-50% as unabsorbed drug.
Category C
Category C
Osteoporosis Agent
Osteoporosis Agent